ADMA Biologics Inc (ADMA)
20.21
-1.26
(-5.89%)
USD |
NASDAQ |
Nov 14, 16:00
20.17
-0.04
(-0.20%)
After-Hours: 20:00
ADMA Biologics Research and Development Expense (Quarterly): 0.412M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.412M |
| June 30, 2024 | 0.56M |
| March 31, 2024 | 0.45M |
| December 31, 2023 | 0.446M |
| September 30, 2023 | 0.596M |
| June 30, 2023 | 1.403M |
| March 31, 2023 | 0.855M |
| December 31, 2022 | 1.075M |
| September 30, 2022 | 1.042M |
| June 30, 2022 | 0.8734M |
| March 31, 2022 | 0.6241M |
| December 31, 2021 | 0.7289M |
| September 30, 2021 | 0.7706M |
| June 30, 2021 | 1.159M |
| March 31, 2021 | 0.9876M |
| December 31, 2020 | 1.014M |
| September 30, 2020 | 1.708M |
| June 30, 2020 | 1.656M |
| March 31, 2020 | 1.529M |
| December 31, 2019 | 0.4648M |
| September 30, 2019 | 0.4914M |
| June 30, 2019 | 0.517M |
| March 31, 2019 | 0.8706M |
| December 31, 2018 | 0.9173M |
| September 30, 2018 | 1.003M |
| Date | Value |
|---|---|
| June 30, 2018 | 1.040M |
| March 31, 2018 | 0.9656M |
| December 31, 2017 | 1.205M |
| September 30, 2017 | 1.814M |
| June 30, 2017 | 1.358M |
| March 31, 2017 | 1.193M |
| December 31, 2016 | 0.5834M |
| September 30, 2016 | 1.677M |
| June 30, 2016 | 3.400M |
| March 31, 2016 | 2.028M |
| December 31, 2015 | 1.997M |
| September 30, 2015 | 2.112M |
| June 30, 2015 | 1.506M |
| March 31, 2015 | 1.402M |
| December 31, 2014 | 1.920M |
| September 30, 2014 | 1.483M |
| June 30, 2014 | 1.784M |
| March 31, 2014 | 4.330M |
| December 31, 2013 | 2.956M |
| September 30, 2013 | 1.409M |
| June 30, 2013 | 3.470M |
| March 31, 2013 | 1.468M |
| December 31, 2012 | 1.268M |
| September 30, 2012 | 1.941M |
| June 30, 2012 | 0.1787M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.412M
Minimum
Sep 2024
1.708M
Maximum
Sep 2020
0.9177M
Average
0.8642M
Median
Research and Development Expense (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 59.34M |
| Madrigal Pharmaceuticals Inc | 68.74M |
| Assembly Biosciences Inc | 16.26M |
| TG Therapeutics Inc | 20.14M |
| Krystal Biotech Inc | 13.51M |